JNJ vs ABT
By Alex · Tickerpine
Johnson & Johnson vs Abbott Laboratories, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | ABT |
|---|---|---|
| Price | $263.81 | $103.70 |
| Market cap | $635.07B | $179.44B |
| P/E ratio | 40.0 | 38.6 |
| ROE | 20.02% | — |
| Profit margin | 16.20% | 9.75% |
| Revenue growth | 5.90% | 14.50% |
| Dividend yield | 2.03% | 2.43% |
| Beta | 0.21 | 0.58 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs ABT in plain English
- JNJ is the bigger company — about 3.5× the market cap of ABT.
- ABT is cheaper on earnings (P/E 38.6 vs 40.0).
- ABT is growing revenue faster (14% vs 6%).
- ABT has the higher dividend yield (2.43% vs 2.03%).
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
ABT return calculator
See what $1,000 in Abbott Laboratories would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.